CA3121064A1 - Antibacterial antisense agents - Google Patents

Antibacterial antisense agents Download PDF

Info

Publication number
CA3121064A1
CA3121064A1 CA3121064A CA3121064A CA3121064A1 CA 3121064 A1 CA3121064 A1 CA 3121064A1 CA 3121064 A CA3121064 A CA 3121064A CA 3121064 A CA3121064 A CA 3121064A CA 3121064 A1 CA3121064 A1 CA 3121064A1
Authority
CA
Canada
Prior art keywords
cat
alkyl
compound according
cca
tcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121064A
Other languages
English (en)
French (fr)
Inventor
Martin Quibell
Timothy SCHULZ-UTERMOEHL
Fraser MURRAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pedanius Therapeutics Ltd
Original Assignee
Pedanius Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedanius Therapeutics Ltd filed Critical Pedanius Therapeutics Ltd
Publication of CA3121064A1 publication Critical patent/CA3121064A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3121064A 2018-11-28 2019-11-27 Antibacterial antisense agents Pending CA3121064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1819399.5 2018-11-28
GB1819399.5A GB2579253A (en) 2018-11-28 2018-11-28 Antibacterial antisense agents
PCT/GB2019/053354 WO2020109792A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents

Publications (1)

Publication Number Publication Date
CA3121064A1 true CA3121064A1 (en) 2020-06-04

Family

ID=65024582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121064A Pending CA3121064A1 (en) 2018-11-28 2019-11-27 Antibacterial antisense agents

Country Status (9)

Country Link
US (1) US20220106595A1 (https=)
EP (1) EP3887520A1 (https=)
JP (1) JP2022510346A (https=)
KR (1) KR20210098493A (https=)
CN (1) CN113366107A (https=)
AU (1) AU2019386368A1 (https=)
CA (1) CA3121064A1 (https=)
GB (1) GB2579253A (https=)
WO (1) WO2020109792A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130516A (en) * 1978-03-31 1979-10-09 Yuuichi Yamamura Acyllnnacetylmuramylpeptide derivativeeantigen combination
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
EP0541486A1 (de) 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
WO2006104530A1 (en) * 2005-03-28 2006-10-05 Cell Works Therapeutics, Inc. Therapeutics targeted to renal cells
US20140073589A1 (en) 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
EP3564374A1 (en) * 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP2845607A1 (en) 2013-09-09 2015-03-11 University of Vienna Antisense oligonucleotides with improved pharmacokinetic properties
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
EP3240794A4 (en) 2014-12-31 2018-10-31 Oregon State University Antisense antibacterial compounds and methods
WO2016172615A1 (en) 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
WO2017010575A1 (ja) * 2015-07-16 2017-01-19 協和発酵キリン株式会社 β２ＧＰＩ遺伝子発現抑制核酸複合体
US11142764B2 (en) 2015-12-23 2021-10-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11180756B2 (en) * 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds

Also Published As

Publication number Publication date
JP2022510346A (ja) 2022-01-26
AU2019386368A1 (en) 2021-07-01
KR20210098493A (ko) 2021-08-10
WO2020109792A1 (en) 2020-06-04
CN113366107A (zh) 2021-09-07
GB2579253A (en) 2020-06-17
GB201819399D0 (en) 2019-01-09
EP3887520A1 (en) 2021-10-06
US20220106595A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
EP2558586B1 (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
AU2025275263A1 (en) Targeting ligands
CN104768964B (zh) 具有胍桥的人工核苷和寡核苷酸
US11542501B2 (en) Antisense oligonucleotides targeting ATXN3
US20240026360A1 (en) Oligonucleotides for modulating tau expression
TW202203972A (zh) 治療性化合物之標靶性配體
US20070275910A1 (en) Phosphoramidate Derivatives
US20210095277A1 (en) Antisense oligonucleotides targeting srebp1
EP4692103A1 (en) Novel targeting compound and use thereof, and nucleic acid conjugate and use thereof
TW202440920A (zh) 雙環脫鹼基核酸類似物以及由它們製備的寡聚化合物
CA3121064A1 (en) Antibacterial antisense agents
CN120209051A (zh) 用于递送的靶向化合物及其用途
WO2019115416A2 (en) Oligonucleotides for modulating fndc3b expression
EP2440533B1 (en) Guanine riboswitch binding compounds and their use as antibiotics
US20220177883A1 (en) Antisense Oligonucleotides Targeting ATXN3
EP2625181B1 (en) Method of preparation of antiviral compounds and useful intermediates thereof
WO2019137974A1 (en) Oligonucleotides for modulating gsk3b expression
AU2024302964A1 (en) Sirna targeting mmp7, sirna conjugate and medical use thereof
AU2023287741A1 (en) Atxn2 rna interference agents
HK40121892A (en) Compound, conjugate, composition, and uses thereof
WO2025095052A1 (ja) 炭素環式ヌクレオシド含有オリゴヌクレオチド
CN119925624A (zh) 肝靶向化合物及其缀合物、制备方法和用途
WO2024099316A1 (zh) 含七元杂环的四价缀合基团及其应用
WO2019145386A1 (en) Oligonucleotides for modulating csnk1d expression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220831